Insider Selling: USANA Health Sciences (NYSE:USNA) Director Sells $17,986.00 in Stock

USANA Health Sciences, Inc. (NYSE:USNA) Director Gilbert Fuller sold 1,058 shares of the business’s stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $17.00, for a total transaction of $17,986.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

USANA Health Sciences Trading Down 1.5%

Shares of USANA Health Sciences stock opened at $16.88 on Monday. The company has a fifty day simple moving average of $20.29 and a 200-day simple moving average of $21.74. The stock has a market cap of $311.66 million, a price-to-earnings ratio of 30.70, a PEG ratio of 0.70 and a beta of 0.64. USANA Health Sciences, Inc. has a 12-month low of $16.72 and a 12-month high of $38.32.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, February 17th. The company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.41 by $0.19. USANA Health Sciences had a net margin of 1.16% and a return on equity of 6.75%. The firm had revenue of $226.20 million for the quarter, compared to analyst estimates of $225.96 million. On average, analysts forecast that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

USNA has been the subject of several research reports. Weiss Ratings reissued a “sell (d)” rating on shares of USANA Health Sciences in a report on Monday, December 29th. Wall Street Zen upgraded USANA Health Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Finally, Zacks Research raised USANA Health Sciences from a “strong sell” rating to a “hold” rating in a research report on Monday, February 16th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce”.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. National Bank of Canada FI raised its holdings in shares of USANA Health Sciences by 166.6% in the third quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock valued at $53,000 after buying an additional 1,201 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of USANA Health Sciences by 382.5% during the second quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock worth $73,000 after buying an additional 1,901 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of USANA Health Sciences by 52.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock worth $106,000 after buying an additional 1,327 shares during the last quarter. Parallel Advisors LLC grew its holdings in shares of USANA Health Sciences by 1,354.3% during the fourth quarter. Parallel Advisors LLC now owns 3,854 shares of the company’s stock worth $76,000 after buying an additional 3,589 shares during the last quarter. Finally, Quantbot Technologies LP increased its position in USANA Health Sciences by 19.5% in the 2nd quarter. Quantbot Technologies LP now owns 3,957 shares of the company’s stock valued at $121,000 after acquiring an additional 646 shares during the period. 54.25% of the stock is currently owned by institutional investors and hedge funds.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.